Royal Bank of Canada’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-22
| Closed | – | – | 7984 |
|
|
2023
Q2 | $0 | Buy |
22
+2
| +10% | +$3 | ﹤0.01% | 8012 |
|
|
2023
Q1 | $0 | Hold |
20
| – | – | ﹤0.01% | 7867 |
|
|
2022
Q4 | $0 | Hold |
20
| – | – | ﹤0.01% | 8216 |
|
|
2022
Q3 | $0 | Hold |
20
| – | – | ﹤0.01% | 8275 |
|
|
2022
Q2 | $0 | Hold |
20
| – | – | ﹤0.01% | 8232 |
|
|
2022
Q1 | $0 | Hold |
20
| – | – | ﹤0.01% | 8329 |
|
|
2021
Q4 | $0 | Hold |
20
| – | – | ﹤0.01% | 8317 |
|
|
2021
Q3 | $1K | Hold |
20
| – | – | ﹤0.01% | 7580 |
|
|
2021
Q2 | $1K | Hold |
20
| – | – | ﹤0.01% | 7425 |
|
|
2021
Q1 | $1K | Hold |
20
| – | – | ﹤0.01% | 7371 |
|
|
2020
Q4 | $1K | Sell |
20
-2
| -9% | -$217 | ﹤0.01% | 7024 |
|
|
2020
Q3 | $3K | Hold |
22
| – | – | ﹤0.01% | 6280 |
|
|
2020
Q2 | $3K | Buy |
22
+8
| +57% | +$1.33K | ﹤0.01% | 6245 |
|
|
2020
Q1 | $2K | Buy |
14
+4
| +40% | +$1.22K | ﹤0.01% | 6377 |
|
|
2019
Q4 | $4K | Hold |
10
| – | – | ﹤0.01% | 6447 |
|
|
2019
Q3 | $5K | Buy |
10
+4
| +67% | +$2.26K | ﹤0.01% | 6072 |
|
|
2019
Q2 | $3K | Sell |
6
-2
| -25% | -$1.23K | ﹤0.01% | 6529 |
|
|
2019
Q1 | $5K | Hold |
8
| – | – | ﹤0.01% | 6303 |
|
|
2018
Q4 | $3K | Sell |
8
-9
| -53% | -$4.84K | ﹤0.01% | 6394 |
|
|
2018
Q3 | $11K | Sell |
17
-37
| -69% | -$26.2K | ﹤0.01% | 5964 |
|
|
2018
Q2 | $47K | Sell |
54
-42
| -44% | -$48.1K | ﹤0.01% | 5185 |
|
|
2018
Q1 | $121K | Sell |
96
-36
| -27% | -$53.2K | ﹤0.01% | 4589 |
|
|
2017
Q4 | $198K | Sell |
132
-117
| -47% | -$185K | ﹤0.01% | 4432 |
|
|
2017
Q3 | $509K | Buy |
249
+38
| +18% | +$89.1K | ﹤0.01% | 3782 |
|
|
2017
Q2 | $553K | Buy |
211
+34
| +19% | +$87.7K | ﹤0.01% | 3588 |
|
|
2017
Q1 | $530K | Buy |
177
+171
| +2,850% | +$416K | ﹤0.01% | 3594 |
|
|
2016
Q4 | $10K | Buy |
+6
| New | +$7.97K | ﹤0.01% | 6103 |
|
Royal Bank of Canada's NBRV Position: Q3 2023 in Review
Royal Bank of Canada sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2023, closing a stake of 22 shares.
Royal Bank of Canada first reported a position in NBRV in Q4 2016 and held it in 27 quarters. The position peaked at $553K in Q2 2017. 0 funds tracked by Wall St. Rank hold NBRV as of Q3 2023.
- Royal Bank of Canada reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2023 after selling out during the quarter.
- Royal Bank of Canada sold 22 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2023.
- Royal Bank of Canada first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2016 and held it in 27 quarters.
- Royal Bank of Canada's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $553K in Q2 2017.
- 0 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2023.
Based on Royal Bank of Canada's 13F filing for Q3 2023, filed 14 Nov 2023.